Biostar Pharmaceuticals Valuation
| BSPMDelisted Stock | USD 0.01 0.00 0.00% |
Biostar Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Biostar Pharmaceuticals from analyzing the firm fundamentals such as Profit Margin of 2.94 %, return on equity of 0.0266, and Current Valuation of 316.46 K as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Biostar Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Biostar Pharmaceuticals is based on 3 months time horizon. Increasing Biostar Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Biostar pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Biostar Pharmaceuticals. Since Biostar Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biostar Pink Sheet. However, Biostar Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.01 | Real 0.0085 | Hype 0.01 |
The intrinsic value of Biostar Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biostar Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biostar Pharmaceuticals helps investors to forecast how Biostar pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biostar Pharmaceuticals more accurately as focusing exclusively on Biostar Pharmaceuticals' fundamentals will not take into account other important factors: Biostar Pharmaceuticals Total Value Analysis
Biostar Pharmaceuticals is currently projected to have valuation of 316.46 K with market capitalization of 94, debt of 0, and cash on hands of 364.97 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biostar Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
316.46 K | 94 | 0 | 364.97 K |
Biostar Pharmaceuticals Investor Information
The company has price-to-book (P/B) ratio of 0.01. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biostar Pharmaceuticals had not issued any dividends in recent years. The entity had 1:7 split on the 5th of February 2016. Based on the key indicators related to Biostar Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Biostar Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Biostar Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biostar Pharmaceuticals has an asset utilization ratio of 0.75 percent. This suggests that the Company is making $0.007477 for each dollar of assets. An increasing asset utilization means that Biostar Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Biostar Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 317.79 K. Net Loss for the year was (5.7 M) with profit before overhead, payroll, taxes, and interest of 915.17 K.About Biostar Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Biostar Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Biostar Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Biostar Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Biostar Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biostar Pharmaceuticals. We calculate exposure to Biostar Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biostar Pharmaceuticals's related companies.Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter and prescription pharmaceutical products for various diseases and conditions in the Peoples Republic of China. The company was incorporated in 2007 and is headquartered in Xianyang, the Peoples Republic of China. Biostar Pharmaceuticals operates under Pharmaceuticals And Biosciences classification in the United States and is traded on OTC Exchange. It employs 200 people.
8 Steps to conduct Biostar Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Biostar Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Biostar Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Biostar Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Biostar Pharmaceuticals' revenue streams: Identify Biostar Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Biostar Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Biostar Pharmaceuticals' growth potential: Evaluate Biostar Pharmaceuticals' management, business model, and growth potential.
- Determine Biostar Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Biostar Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Biostar Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Biostar Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.3 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Biostar Pink Sheet
If you are still planning to invest in Biostar Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostar Pharmaceuticals' history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |